Karen Knudsen, Chief Executive Officer at Parker Institute for Cancer Immunotherapy, shared a post on LinkedIn:
“Fantastic start to Cancer 2035 with Tony Letai and Mike Milken, building a consensus around the importance of therapeutic vaccine development to eradicate cancers. This is a major focus for us at the Parker Institute for Cancer Immunotherapy, and I could not agree more with the promise of these technologies!”
Other articles featuring Karen Knudsen on OncoDaily.